![Page 1: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/1.jpg)
Practical Implementation as a Discussion with the Patient
Practical Use of SGLT-2 Inhibitors in T2DM:
Clinical Pearls- Perlas de SabiduriaClinical Pearls- Perlas de Sabiduria
Stan Schwartz MD, FACPAffiliate, Main Line Health System
Emeritus, Clinical Associate Professor of Medicine, U of Pa.
![Page 2: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/2.jpg)
Structure of Our Discussion:1.Following Flow of Discussion with Patient
1. General principles2. SGLT-2 Principles
2.First Visit Process of Care3.Follow-up Visit Process of Care
![Page 3: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/3.jpg)
Updated Natural History of Type 2 Diabetes
Risk of Dev. Complications
ETOHBPSmoking
EyeNerveKidney
BlindnessAmputationCRF
Disability
Disability
MICVAAmp
Age 0-15 15-40+ 15-50+25-70+
Macrovascular Complications
IGT Type II DM
Microvascular Complications
DEATHpp>7.8
β-Cell secretion/massGene
Environmental Inflam. Triggerseg: viral,endocrine disruptors, food AGE’s, biome
endocrine disruptors, food AGE’s ,biomeEnvironmental Triggers
Resistance inflammatory, adipokines
Resistance-FFAPoor diet, inactivity
EPIGENITICS
EPIGENITICS
Polygenic- other
Monogenic (HLA)
Polygenic
Monogenic – MODY
IR Phenotype
![Page 4: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/4.jpg)
Treat Aggressivelyto Delay or Prevent
Complications
Pearl
![Page 5: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/5.jpg)
Impact of Intensive Therapy in Type 2 Diabetes Summary of Major Clinical Trials:
BUT Subset Evaluations Show Reduced CV Outcomes if shorter duration of DM, without significant pre-existing complications
Study Microvascular Macrovascular Mortality
UGDP ↔ ↔ ↔UKPDS ↓ ↓ ↔ ↓ ↔ ↓
DCCT/EDIC* ↓ ↓ ↔ ↓ ↔ ↔ACCORD ↓ ↔ ↑(unadj.), ↔ (adj.)
ADVANCE ↓ ↔ ↔VADT ↔ ↔ ↔
Initial Trial Long Term Follow-up
↑↑- likely due to hypoglycemia and weight gain- likely due to hypoglycemia and weight gain
![Page 6: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/6.jpg)
Early Treatment Decreases Micro and Macro Vascular RISK/
OUTCOMES
As long as do without Undue Hypoglycemia or Weight Gain
Pearl
![Page 7: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/7.jpg)
Consequences of Hypoglycemia• Prolonged QT- intervals- Diabetologia 52:42,2009
– Can be of pronged duration IJCP Sup 129, 7/02
– Greater with higher catecholamine levels Europace 10,860
• Associated with Angina Diabetes Care 26, 1485, 2003 / Ischemic EKG changes Porcellati, ADA2010
• Associated with Arrhythmias• Associated with Sudden Death Endocrine Practice 16,¾ 2010
• Increased Variabilty- explains highest mortality in intensive group had highest HgA1c in ACCORD ( increases inflammation, ICU mortality Hirsch ADA2010)
• Sulfonylureas block Ischemic Preconditioning
![Page 8: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/8.jpg)
There is No perfect Exogenous Insulin:All result in HyperInsulinemia and Potential Hypoglycemia
Exogenous Insulin
Perfect glucose sensor-Insulin secretion modulator
Hypoglycemia/ Wt. Gain
NORMAL:Insulin into portal system
and B-cell=
CONCLUSION:DELAY INSULIN THERAPY;AVOID BOLUS RX if possible
![Page 9: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/9.jpg)
PearlNo more Sulfonylureas or Glinides
Delay InsulinMost will not need Bolus Insulin
![Page 10: Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz](https://reader036.vdocument.in/reader036/viewer/2022062413/5a4d1b727f8b9ab0599b5f29/html5/thumbnails/10.jpg)
HYPERGLYCEMIA
7. Stomach/Small intestine
10. Kidney
11. Immune System / Inflammation
4. Increased hepatic glucose production
8. Colon / Biome
6. Adipose
5. Decreased peripheral muscle uptake
9. Brain
IncretinDopa agonist
SGLT2 Inhibitors
Anti-Inflam-matories,Immune modulators Metformin, TZDs
Metformin, TZDs
Metformin, TZDs
Incretins/Probiotics
GLP-1 RAsAGIPramlintide
1. Decreased insulin secretion
Incretins Ranolazine
2. Unsuppressed
glucagon secretion
Incretins Pramlintide
3. Decreased incretin effect
Incretins
BETA CELL-CENTRIC VIEW OF DIABETES: Matching Rx with Etiologyuse least number agents treating maximal # of modes of hyperglycemiaFOCUS on SGLT-2 Inhibition- addresses 5/11 MOH
COREDEFECT
Resistance IssuesNew ConstructOlder ConstructIslet Cell Issues